|
1
|
Grafe I, Alexander S, Peterson JR, Snider
TN, Levi B, Lee B and Mishina Y: TGF-β family signaling in
mesenchymal differentiation. Cold Spring Harb Perspect Biol.
10:a0222022018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yang X, Tian S, Fan L, Niu R, Yan M, Chen
S, Zheng M and Zhang S: Integrated regulation of chondrogenic
differentiation in mesenchymal stem cells and differentiation of
cancer cells. Cancer Cell Int. 22:1692022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yao JC, Oetjen KA, Wang T, Xu H, Abou-Ezzi
G, Krambs JR, Uttarwar S, Duncavage EJ and Link DC: TGF-β signaling
in myeloproliferative neoplasms contributes to myelofibrosis
without disrupting the hematopoietic niche. J Clin Invest.
132:e1540922022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wei E, Hu M, Wu L, Pan X, Zhu Q, Liu H and
Liu Y: TGF-β signaling regulates differentiation of MSCs in bone
metabolism: Disputes among viewpoints. Stem Cell Res Ther.
15:1562024. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu F, Xie J, Zhang X, Wu Z, Zhang S, Xue
M, Chen J, Yang Y and Qiu H: Overexpressing TGF-β1 in mesenchymal
stem cells attenuates organ dysfunction during CLP-induced septic
mice by reducing macrophage-driven inflammation. Stem Cell Res
Ther. 11:3782020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wan M, Li C, Zhen G, Jiao K, He W, Jia X,
Wang W, Shi C, Xing Q, Chen YF, et al: Injury-activated
transforming growth factor β controls mobilization of mesenchymal
stem cells for tissue remodeling. Stem Cells. 30:2498–2511. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fan XL, Zhang Y, Li X and Fu QL:
Mechanisms underlying the protective effects of mesenchymal stem
cell-based therapy. Cell Mol Life Sci. 77:2771–2794. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Denko NC and Giaccia AJ: Tumor hypoxia,
the physiological link between Trousseau's syndrome
(carcinoma-induced coagulopathy) and metastasis. Cancer Res.
61:795–798. 2001.PubMed/NCBI
|
|
9
|
Emami Nejad A, Najafgholian S, Rostami A,
Sistani A, Shojaeifar S, Esparvarinha M, Nedaeinia R, Haghjooy
Javanmard S, Taherian M, Ahmadlou M, et al: The role of hypoxia in
the tumor microenvironment and development of cancer stem cell: A
novel approach to developing treatment. Cancer Cell Int. 21:622021.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liang W and Chen X, Zhang S, Fang J, Chen
M, Xu Y and Chen X: Mesenchymal stem cells as a double-edged sword
in tumor growth: Focusing on MSC-derived cytokines. Cell Mol Biol
Lett. 26:32021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Aravindhan S, Ejam SS, Lafta MH, Markov A,
Yumashev AV and Ahmadi M: Mesenchymal stem cells and cancer
therapy: Insights into targeting the tumour vasculature. Cancer
Cell Int. 21:1582021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Andonegui-Elguera MA, Alfaro-Mora Y,
Cáceres-Gutiérrez R, Caro-Sánchez CHS, Herrera LA and Díaz-Chávez
J: An overview of vasculogenic mimicry in breast cancer. Front
Oncol. 10:2202020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yao J, Sun L, Gao F and Zhu W: Mesenchymal
stem/stromal cells: Dedicator to maintain tumor homeostasis. Hum
Cell. 38:212024. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
den Hollander P, Maddela JJ and Mani SA:
Spatial and temporal relationship between epithelial-mesenchymal
transition (EMT) and stem cells in cancer. Clin Chem. 70:190–205.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hass R: Role of MSC in the tumor
microenvironment. Cancers (Basel). 12:21072020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hill BS, Pelagalli A, Passaro N and
Zannetti A: Tumor-educated mesenchymal stem cells promote
pro-metastatic phenotype. Oncotarget. 8:73296–73311. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fasano M, Pirozzi M, Miceli CC, Cocule M,
Caraglia M, Boccellino M, Vitale P, De Falco V, Farese S, Zotta A,
et al: TGF-β modulated pathways in colorectal cancer: New potential
therapeutic opportunities. Int J Mol Sci. 25:74002024. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sritharan S and Sivalingam N: Secretion of
IL-6 and TGF-β2 by colon cancer cells may promote resistance to
chemotherapy. Ind J Clin Biochem. 2024. View Article : Google Scholar
|
|
19
|
Dumont N and Arteaga CL: Transforming
growth factor-beta and breast cancer: Tumor promoting effects of
transforming growth factor-beta. Breast Cancer Res. 2:125–132.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang K, Han Y, Chen Y, Shen H, Zeng S and
Cai C: Tumor metabolic regulators: Key drivers of metabolic
reprogramming and the promising targets in cancer therapy. Mol
Cancer. 24:72025. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang H, Li S, Wang D, Liu S, Xiao T, Gu
W, Yang H, Wang H, Yang M and Chen P: Metabolic reprogramming and
immune evasion: The interplay in the tumor microenvironment.
Biomark Res. 12:962024. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Paul D and Nedelcu AM: The underexplored
links between cancer and the internal body climate: Implications
for cancer prevention and treatment. Front Oncol. 12:10400342022.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Slominski RM, Raman C, Chen JY and
Slominski AT: How cancer hijacks the body's homeostasis through the
neuroendocrine system. Trends Neurosci. 46:263–275. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Roy ME, Veilleux C and Annabi B: In vitro
biomaterial priming of human mesenchymal stromal/stem cells:
Implication of the Src/JAK/STAT3 pathway in vasculogenic mimicry.
Sci Rep. 14:214442024. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schneider CA, Rasband WS and Eliceiri KW:
NIH image to ImageJ: 25 Years of image analysis. Nat Methods.
9:671–675. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Roy ME, Veilleux C, Paquin A, Gagnon A and
Annabi B: Transcriptional regulation of CYR61 and CTGF by LM98: A
synthetic YAP-TEAD inhibitor that targets in-vitro vasculogenic
mimicry in glioblastoma cells. Anticancer Drugs. 35:709–719. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pratt J, Haidara K and Annabi B: MT1-MMP
expression levels and catalytic functions dictate LDL
receptor-related protein-1 ligand internalization capacity in U87
glioblastoma cells. Int J Mol Sci. 23:142142022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Holmgaard RB, Schaer DA, Li Y, Castaneda
SP, Murphy MY, Xu X, Inigo I, Dobkin J, Manro JR, Iversen PW, et
al: Targeting the TGFβ pathway with galunisertib, a TGFβRI small
molecule inhibitor, promotes anti-tumor immunity leading to
durable, complete responses, as monotherapy and in combination with
checkpoint blockade. J Immunother Cancer. 6:472018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sicard AA, Suarez NG, Cappadocia L and
Annabi B: Functional targeting of the TGF-βR1 kinase domain and
downstream signaling: A role for the galloyl moiety of green
tea-derived catechins in ES-2 ovarian clear cell carcinoma. J Nutr
Biochem. 87:1085182021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Djediai S, Gonzalez Suarez N, El
Cheikh-Hussein L, Rodriguez Torres S, Gresseau L, Dhayne S,
Joly-Lopez Z and Annabi B: MT1-MMP cooperates with TGF-β
receptor-mediated signaling to trigger SNAIL and Induce
epithelial-to-mesenchymal-like transition in U87 glioblastoma
cells. Int J Mol Sci. 22:130062021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Antoon R, Overdevest N, Saleh AH and
Keating A: Mesenchymal stromal cells as cancer promoters. Oncogene.
43:3545–3555. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu S, Ren J, Hu Y, Zhou F and Zhang L:
TGFβ family signaling in human stem cell self-renewal and
differentiation. Cell Regen. 13:262024. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang J, Peng J, Chen Y, Nasser MI and Qin
H: The role of stromal cells in epithelial-mesenchymal plasticity
and its therapeutic potential. Discov Oncol. 15:132024. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Novoseletskaya ES, Evdokimov PV and
Efimenko AY: Extracellular matrix-induced signaling pathways in
mesenchymal stem/stromal cells. Cell Commun Signal. 21:2442023.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nam D, Park A, Dubon MJ, Yu J, Kim W, Son
Y and Park KS: Coordinated regulation of mesenchymal stem cell
migration by various chemotactic stimuli. Int J Mol Sci.
21:85612020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cottler-Fox MH, Lapidot T, Petit I, Kollet
O, DiPersio JF, Link D and Devine S: Stem cell mobilization.
Hematology Am Soc Hematol Educ Program. 419–437. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ridge SM, Sullivan FJ and Glynn SA:
Mesenchymal stem cells: Key players in cancer progression. Mol
Cancer. 16:312017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Annabi B, Naud E, Lee YT, Eliopoulos N and
Galipeau J: Vascular progenitors derived from murine bone marrow
stromal cells are regulated by fibroblast growth factor and are
avidly recruited by vascularizing tumors. J Cell Biochem.
91:1146–1158. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Frisbie L, Buckanovich RJ and Coffman L:
Carcinoma-associated mesenchymal stem/stromal cells: Architects of
the pro-tumorigenic tumor microenvironment. Stem Cells. 40:705–715.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang J, Qiao L, Liang N, Xie J, Luo H,
Deng G and Zhang J: Vasculogenic mimicry and tumor metastasis. J
BUON. 21:533–541. 2016.PubMed/NCBI
|
|
42
|
Zonneville J, Safina A, Truskinovsky AM,
Arteaga CL and Bakin AV: TGF-β signaling promotes tumor vasculature
by enhancing the pericyte-endothelium association. BMC Cancer.
18:6702018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yoshimura A and Muto G: TGF-β function in
immune suppression. Curr Top Microbiol Immunol. 350:127–147.
2011.PubMed/NCBI
|
|
44
|
Konkel JE, Zhang D, Zanvit P, Chia C,
Zangarle-Murray T, Jin W, Wang S and Chen W: Transforming growth
factor-β signaling in regulatory T cells controls T helper-17 cells
and tissue-specific immune responses. Immunity. 46:660–674. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Guo C, Sun H, Du Y, Dai X, Pang Y, Han Z,
Xiong X, Li S, Zhang J, Zheng Q and Gui X: Specifically blocking
αvβ8-mediated TGF-β signaling to reverse immunosuppression by
modulating macrophage polarization. J Exp Clin Cancer Res.
44:12025. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Itoh F, Itoh S, Adachi T, Ichikawa K,
Matsumura Y, Takagi T, Festing M, Watanabe T, Weinstein M, Karlsson
S and Kato M: Smad2/Smad3 in endothelium is indispensable for
vascular stability via S1PR1 and N-cadherin expressions. Blood.
119:5320–5628. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Tashima T: Mesenchymal stem cell
(MSC)-based drug delivery into the brain across the blood-brain
barrier. Pharmaceutics. 16:2892024. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Minev T, Balbuena S, Gill JM, Marincola
FM, Kesari S and Lin F: Mesenchymal stem cells-the secret agents of
cancer immunotherapy: Promises, challenges, and surprising twists.
Oncotarget. 15:793–805. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wu X, Jiang J, Gu Z, Zhang J, Chen Y and
Liu X: Mesenchymal stromal cell therapies: Immunomodulatory
properties and clinical progress. Stem Cell Res Ther. 11:3452020.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Lan T, Luo M and Wei X: Mesenchymal
stem/stromal cells in cancer therapy. J Hematol Oncol. 14:1952021.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kim BG, Malek E, Choi SH, Ignatz-Hoover JJ
and Driscoll JJ: Novel therapies emerging in oncology to target the
TGF-β pathway. J Hematol Oncol. 14:552021. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Guo Y, Wang Z, Zhou H, Pan H, Han W, Deng
Y, Li Q, Xue J, Ge X, Wang S, et al: First-in-human study of
GFH018, a small molecule inhibitor of transforming growth factor-β
receptor I inhibitor, in patients with advanced solid tumors. BMC
Cancer. 24:4442024. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Margiana R, Markov A, Zekiy AO, Hamza MU,
Al-Dabbagh KA, Al-Zubaidi SH, Hameed NM, Ahmad I, Sivaraman R, Kzar
HH, et al: Clinical application of mesenchymal stem cell in
regenerative medicine: a narrative review. Stem Cell Res Ther.
13:3662022. View Article : Google Scholar : PubMed/NCBI
|
